跳至主要内容
临床试验/JPRN-UMIN000006708
JPRN-UMIN000006708已完成2 期

Phase II study of Letrozole combined with Cyclophosphamide and Capecitabine(LCX) for Hormone-Sensitive advanced breast cancer(age over 65) (JBCRG-14) - JBCRG-14

Japan Breast Cancer Research Group (JBCRG)0 个研究点目标入组 32 人开始时间: 2011年11月18日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
32

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
65years-old 至 80years-old(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1. Prior chemotherapy or endocrine therapy 2. Need for treatment with taxanes and anthracycline drug 3. need of Treatment with hormone therapy alone 4. Medication that may affect the sex hormone status (hormone replacement therapy, raloxifene, etc.) 5. History or complications of uncontrolled hypertension, severe heart disease (heart failure, ischemic heart disease, endocarditis, valvular heart disease, pericarditis, and congenital heart disease) 6. Active double cancer 7. Inflammatory breast cancer 8. Bilateral breast cancer 9. Medication of investigational new drug 10. Cases in which study participation is considered difficult due to the coexistence of psychosis or psychiatric symptoms 11. Cases considered ineligible by the attending physician for other reasons

研究者

发起方
Japan Breast Cancer Research Group (JBCRG)

相似试验